Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
India had proposed for setting up the global standards for millets
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Subscribe To Our Newsletter & Stay Updated
